KRYSTAL-2: A phase I/II trial of adagrasib (MRTX849) in combination with TNO155 in patients with advanced solid tumors with KRAS G12C mutation.

Joshua K. Sabari,Haeseong Park,Anthony W. Tolcher,Sai-Hong Ignatius Ou,Edward B. Garon,Ben George,Pasi A. Jänne,Susan Moody,Eugene Y. Tan,Suman Sen,Dana Peters,Xiaohong Yan,James G. Christensen,Andrew S. Chi,Rebecca S. Heist

KRYSTAL-2: A phase I/II trial of adagrasib (MRTX849) in combination with TNO155 in patients with advanced solid tumors with KRAS G12C mutation.

2021

Joshua K. Sabari
Haeseong Park
Anthony W. Tolcher
Sai-Hong Ignatius Ou
Edward B. Garon
Ben George
Pasi A. Jänne
Susan Moody
Eugene Y. Tan
Suman Sen
Dana Peters
Xiaohong Yan
James G. Christensen
Andrew S. Chi
Rebecca S. Heist

TPS146Background: KRAS is the most frequently mutated oncogene in cancer and a key mediator of the RAS/MAPK signaling cascade that promotes cellular growth and proliferation. KRAS G12C tumor mutati...

Keywords:

Cell growth
KRAS
Cancer
Oncogene
in patient
Mutation
Mediator
phase i ii
Medicine
Cancer research

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations